Antibacterial Performance of Polydopamine-Modified Polymer Surfaces Containing Passive and Active Components

Abstract

A growing number of device-related nosocomial infections, elevated hospitalization costs, and patient morbidity necessitate the development of novel antibacterial strategies for clinical devices. We have previously demonstrated a simple, aqueous polydopamine dip-coating method to functionalize surfaces for a wide variety of uses. Here, we extend this strategy with the goal of imparting antifouling and antimicrobial properties to substrates, exploiting the ability of polydopamine to immobilize polymers and induce metal nanoparticle formation. Polydopamine was deposited as a thin adherent film of 4 nm thickness from alkaline aqueous solution onto polycarbonate substrates, followed by grafting of antifouling polymer polyethylene glycol and in situ deposition of silver nanoparticles onto the polydopamine coated polycarbonate substrates. Elemental and morphological surface analyses confirmed successful grafting of polyethylene glycol brushes onto polydopamine-coated substrates, as well as spontaneous silver nanoparticle formation for polydopamine-coated substrates incubated in silver-nitrate solutions. Sustained silver release was observed over at least 7 days from silver-coated substrates, and the release kinetics could be modulated via additional polydopamine overlayers. In vitro functional assays employing gram negative and positive strains demonstrated dual fouling resistance and antibacterial properties of the coatings due to the fouling resistance of grafted polyethylene glycol and antibacterial effect of silver, respectively. Polycarbonate substrates coated only with silver using a method similar to existing commercial coatings provided an antibacterial effect but failed to inhibit bacterial attachment. Taking into account the previously demonstrated substrate versatility of polydopamine coatings, our findings suggest that this strategy could be implemented on a variety of substrate materials to simultaneously improve antifouling and antimicrobial performance.

Antibiotic-decorated titanium with enhanced antibacterial activity through adhesive polydopamine for dental/bone implant

“…Antibacterial copolymers (containing poly(ethylene glycol) (PEG)-based polymers and quaternary ammonium-based polymers) [1,12,14,15,30,34] and silver ion [34] were immobilized onto Ti implants using pDA coating in previous studies by other groups and some prospective results were achieved. For example, thiol-terminated methoxy-PEG was used to graft onto pDA-coated substrates, and these modified surfaces exhibited antifouling property against bacterial and mammalian cells [1,27]. PEG or PEGbased coatings, as a passive strategy, have been of great interest in the drive to develop antifouling surfaces, which rely on physical prevention of bacteria and cell attachment rather than eradicating bacteria [12].…”

Antifouling coating with controllable and sustained silver release for long‐term inhibition of infection and encrustation in urinary catheters

“…22 The formed PDA layer is able to reduce and electrolessly metalize silver ions into silver nanoparticles (AgNPs), and stabilizes and protects the AgNPs from oxidization and aggregation. 23,24 Although there is an earlier study on the use of PDA-reduced AgNPs for antibacterial purpose, 25 little work has been done to control the amount of silver loaded and its release profile for long-term applications. Thus, in the present work, the number of PDA and AgNP layers on the catheter surface was varied and the antibacterial and anti-encrustation efficacy of the coated catheter was investigated.…”

Recent Progress of Mussel‐Inspired Underwater Adhesives

“…Therefore, polydopamine is usually used in solid surface modification. [15][16][17] Xie and Yao et al [18] fabricated a functional Au electrode modified with polydopamine film to immobilize anti-human immunoglobulin G (lgG). Compared to a polypyrrole film modified with anti-human IgG, the prepared electrode possessed a larger amount of specific binding sites for human IgG by subsequent immunoreaction tests.…”